Well actually AVNR isn't quite at its all-time low yet. The stock went through a rev-split on the 18th of January. It was worth approximately $3.75 if I remember correctly. Effectively quadrupling it to about $15 or so. What interests me though is the stock started on its downhill run on great news. Their new brainchild, Nuerodex, which is the only drug of it's kind and expected to rake in millions because of exclusive patents, was granted FDA priority review meaning it will hit the market - on a favorable reply of course - faster than most other drugs would. According to the annual report, they decided on the rev-split to make the stock more appealing to the common investor with a higer price. Alot of good that's doing them now. Soon it will be back to square one with 1/4 less overall shares.